Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Targeted deletion of Sost distal enhancer increases bone formation and bone mass.

Collette NM, Genetos DC, Economides AN, Xie L, Shahnazari M, Yao W, Lane NE, Harland RM, Loots GG.

Proc Natl Acad Sci U S A. 2012 Aug 28;109(35):14092-7. doi: 10.1073/pnas.1207188109. Epub 2012 Aug 10.

2.

Control of the SOST bone enhancer by PTH using MEF2 transcription factors.

Leupin O, Kramer I, Collette NM, Loots GG, Natt F, Kneissel M, Keller H.

J Bone Miner Res. 2007 Dec;22(12):1957-67.

3.

Mef2c deletion in osteocytes results in increased bone mass.

Kramer I, Baertschi S, Halleux C, Keller H, Kneissel M.

J Bone Miner Res. 2012 Feb;27(2):360-73. doi: 10.1002/jbmr.1492.

4.
5.

Sclerostin: current knowledge and future perspectives.

Moester MJ, Papapoulos SE, Löwik CW, van Bezooijen RL.

Calcif Tissue Int. 2010 Aug;87(2):99-107. doi: 10.1007/s00223-010-9372-1. Epub 2010 May 15. Review.

6.

Genomic deletion of a long-range bone enhancer misregulates sclerostin in Van Buchem disease.

Loots GG, Kneissel M, Keller H, Baptist M, Chang J, Collette NM, Ovcharenko D, Plajzer-Frick I, Rubin EM.

Genome Res. 2005 Jul;15(7):928-35. Epub 2005 Jun 17.

7.

SOST/sclerostin, an osteocyte-derived negative regulator of bone formation.

van Bezooijen RL, ten Dijke P, Papapoulos SE, Löwik CW.

Cytokine Growth Factor Rev. 2005 Jun;16(3):319-27. Review.

PMID:
15869900
8.

Sost, independent of the non-coding enhancer ECR5, is required for bone mechanoadaptation.

Robling AG, Kang KS, Bullock WA, Foster WH, Murugesh D, Loots GG, Genetos DC.

Bone. 2016 Nov;92:180-188. doi: 10.1016/j.bone.2016.09.001. Epub 2016 Sep 4.

PMID:
27601226
9.

HDAC5 controls MEF2C-driven sclerostin expression in osteocytes.

Wein MN, Spatz J, Nishimori S, Doench J, Root D, Babij P, Nagano K, Baron R, Brooks D, Bouxsein M, Pajevic PD, Kronenberg HM.

J Bone Miner Res. 2015 Mar;30(3):400-11. doi: 10.1002/jbmr.2381.

10.

Lipoprotein receptor-related protein 6 is required for parathyroid hormone-induced Sost suppression.

Li C, Wang W, Xie L, Luo X, Cao X, Wan M.

Ann N Y Acad Sci. 2016 Jan;1364:62-73. doi: 10.1111/nyas.12750. Epub 2015 Apr 2.

11.

TGF-β regulates sclerostin expression via the ECR5 enhancer.

Loots GG, Keller H, Leupin O, Murugesh D, Collette NM, Genetos DC.

Bone. 2012 Mar;50(3):663-9. doi: 10.1016/j.bone.2011.11.016. Epub 2011 Dec 2.

12.

Sost downregulation and local Wnt signaling are required for the osteogenic response to mechanical loading.

Tu X, Rhee Y, Condon KW, Bivi N, Allen MR, Dwyer D, Stolina M, Turner CH, Robling AG, Plotkin LI, Bellido T.

Bone. 2012 Jan;50(1):209-17. doi: 10.1016/j.bone.2011.10.025. Epub 2011 Oct 30.

13.

Novel SOST gene mutation in a sclerosteosis patient from Morocco: a case report.

Belkhribchia MR, Collet C, Laplanche JL, Hassani R.

Eur J Med Genet. 2014 Mar;57(4):133-7. doi: 10.1016/j.ejmg.2014.02.007. Epub 2014 Mar 1.

PMID:
24594238
14.

Identification of the disease-causing gene in sclerosteosis--discovery of a novel bone anabolic target?

Balemans W, Van Hul W.

J Musculoskelet Neuronal Interact. 2004 Jun;4(2):139-42. Review.

15.

PTH receptor signaling in osteocytes governs periosteal bone formation and intracortical remodeling.

Rhee Y, Allen MR, Condon K, Lezcano V, Ronda AC, Galli C, Olivos N, Passeri G, O'Brien CA, Bivi N, Plotkin LI, Bellido T.

J Bone Miner Res. 2011 May;26(5):1035-46. doi: 10.1002/jbmr.304.

16.

Osteocyte-derived sclerostin inhibits bone formation: its role in bone morphogenetic protein and Wnt signaling.

ten Dijke P, Krause C, de Gorter DJ, Löwik CW, van Bezooijen RL.

J Bone Joint Surg Am. 2008 Feb;90 Suppl 1:31-5. doi: 10.2106/JBJS.G.01183. Review.

PMID:
18292354
17.

A generalized skeletal hyperostosis in two siblings caused by a novel mutation in the SOST gene.

Balemans W, Cleiren E, Siebers U, Horst J, Van Hul W.

Bone. 2005 Jun;36(6):943-7.

PMID:
15869924
18.

Sost and its paralog Sostdc1 coordinate digit number in a Gli3-dependent manner.

Collette NM, Yee CS, Murugesh D, Sebastian A, Taher L, Gale NW, Economides AN, Harland RM, Loots GG.

Dev Biol. 2013 Nov 1;383(1):90-105. doi: 10.1016/j.ydbio.2013.08.015. Epub 2013 Aug 29.

19.

Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength.

Li X, Ominsky MS, Niu QT, Sun N, Daugherty B, D'Agostin D, Kurahara C, Gao Y, Cao J, Gong J, Asuncion F, Barrero M, Warmington K, Dwyer D, Stolina M, Morony S, Sarosi I, Kostenuik PJ, Lacey DL, Simonet WS, Ke HZ, Paszty C.

J Bone Miner Res. 2008 Jun;23(6):860-9. doi: 10.1359/jbmr.080216.

20.

Regulation of beta catenin signaling and parathyroid hormone anabolic effects in bone by the matricellular protein periostin.

Bonnet N, Conway SJ, Ferrari SL.

Proc Natl Acad Sci U S A. 2012 Sep 11;109(37):15048-53. doi: 10.1073/pnas.1203085109. Epub 2012 Aug 27.

Supplemental Content

Support Center